- Home
- ENLT vs IBRX Comparison
ENLT vs IBRX Comparison
Compare ENLT & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ENLT | IBRX |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 6.1B |
| IPO Year | 2022 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ENLT | IBRX |
|---|---|---|
| Price | $77.10 | $8.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $45.17 | $12.50 |
| AVG Volume (30 Days) | 165.0K | ★ 31.8M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $113,288,000.00 |
| Revenue This Year | $403.69 | $88.57 |
| Revenue Next Year | N/A | $146.98 |
| P/E Ratio | $76.10 | ★ N/A |
| Revenue Growth | N/A | ★ 668.31 |
| 52 Week Low | $14.01 | $1.83 |
| 52 Week High | $81.28 | $12.43 |
Technical Indicators
Market Signals| Indicator | ENLT | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 68.67 | 54.98 |
| Support Level | $34.42 | $2.23 |
| Resistance Level | $81.28 | $12.43 |
| Average True Range (ATR) | 3.10 | 1.27 |
| MACD | 0.22 | -0.16 |
| Stochastic Oscillator | 73.03 | 41.62 |
Price Performance
Historical ComparisonAbout ENLT Enlight Renewable Energy Ltd.
Enlight Renewable Energy Ltd develops, finances, constructs, owns, and operates utility-scale renewable energy projects. The company's operating segments are the MENA segment, Europe segment, U.S.A segment, and Others. It generates the majority of its revenue from the Europe segment, which produces its revenue from the sale of the electricity that is produced through wind energy and solar energy in Europe.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.